GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Oncotherapy PLC (LSE:AVO) » Definitions » Price-to-Owner-Earnings

Advanced Oncotherapy (LSE:AVO) Price-to-Owner-Earnings : (As of May. 16, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Advanced Oncotherapy Price-to-Owner-Earnings?

As of today (2024-05-16), Advanced Oncotherapy's share price is £0.01925. Advanced Oncotherapy does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Advanced Oncotherapy's Price-to-Owner-Earnings or its related term are showing as below:


LSE:AVO's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 33.93
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-16), Advanced Oncotherapy's share price is £0.01925. Advanced Oncotherapy's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was £-0.07. Therefore, Advanced Oncotherapy's PE Ratio for today is At Loss.

As of today (2024-05-16), Advanced Oncotherapy's share price is £0.01925. Advanced Oncotherapy's EPS without NRI for the trailing twelve months (TTM) ended in was £-0.07. Therefore, Advanced Oncotherapy's PE Ratio without NRI for today is At Loss.


Advanced Oncotherapy Price-to-Owner-Earnings Historical Data

The historical data trend for Advanced Oncotherapy's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Oncotherapy Price-to-Owner-Earnings Chart

Advanced Oncotherapy Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Advanced Oncotherapy Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Advanced Oncotherapy's Price-to-Owner-Earnings

For the Medical Devices subindustry, Advanced Oncotherapy's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Oncotherapy's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Oncotherapy's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Advanced Oncotherapy's Price-to-Owner-Earnings falls into.



Advanced Oncotherapy Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Advanced Oncotherapy's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.01925/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced Oncotherapy  (LSE:AVO) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Advanced Oncotherapy Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Advanced Oncotherapy's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Oncotherapy (LSE:AVO) Business Description

Traded in Other Exchanges
N/A
Address
4 Tenterden Street, Third Floor, London, GBR, W1S 1TE
Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.